Table 4.
Dose interventions per patient
| Imatinib (n = 70) | Sunitinib (n = 27) | Pazopanib (n = 12) | Total (n = 109) | |
|---|---|---|---|---|
| Dosage advices by hospital pharmacist (n = 109) | ||||
| Patients with the advice to maintain current dose, n (%) | 27 (38.6) | 5 (18.5) | 5 (41.7) | 37 (33.9) |
| Patients with dose adjustment advice, n (%) | 43 (61.4) | 22 (81.5) | 7 (58.3) | 72 (66.1) |
| Implementation of proposed dose interventions (n = 72) | ||||
| Patients for whom proposed interventions were implemented, n (% of proposed interventions) | 20 (46.5) | 17 (77.3) | 4 (57.1) | 41 (56.9) |
| Patients for whom proposed interventions were not implemented, n (% of proposed interventions) | 23 (43.5) | 5 (22.7) | 3 (42.9) | 31 (43.1) |
| Effect of dose interventions (n = 41) | ||||
| Patients with adequate C trough after intervention, n (% of implemented interventions) | 19 (95.0) | 13 (76.5) | 3 (75.0) | 35 (85.4) |
| Patients with inadequate C trough despite intervention, n (% of implemented interventions) | 1 (5%) | 4 (23.5) | 1 (25.0) | 6 (14.6) |
GIST: gastrointestinal stromal tumour; ALL: acute lymphoblastic leukaemia; CML: chronic myeloid leukaemia; mRCC: metastatic renal cell carcinoma; STS: soft tissue sarcoma; cKIT: proto‐oncogene cKIT; BCR‐Abl: fusion gene of breakpoint cluster region gene and Abelson murine leukaemia viral oncogene; PDGFRA: platelet‐derived growth factor receptor‐α; Ctrough: trough level.